Twist Bioscience Targets Up to $560 Million in FY2027 Revenue

Twist Bioscience set a fiscal 2027 revenue target of $550 million to $560 million, projecting about 21% year-over-year growth at the midpoint and positive adjusted EBITDA for the year.

The outlook includes $100 million in revenue from AI drug discovery. Twist also expects sequential growth in DNA Synthesis and Protein Solutions and NGS Applications.

For its first fiscal quarter of 2027, the company expects revenue of $130 million to $132 million. That range represents about 26% year-over-year growth at the midpoint.

Twist plans about $75 million in capital expenditures as part of a two-year investment plan. The forecast excludes tenant improvements funded by landlords.

For fiscal 2026, Twist recorded $459.4 million in revenue, up 22% from $376.6 million a year earlier. Its adjusted EBITDA, a non-GAAP measure, was negative $35.9 million for the full year, with positive adjusted EBITDA of $2.2 million in the fourth quarter. The company reported a fiscal 2026 net loss of $130.2 million.